CSBR

Champions Oncology, Inc. Common Stock

CSBR
Closed
$5.81
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Country

US

CEO

Mr. Robert Brainin

IPO date

1988

Employees

213

ISIN

US15870P3073

Key stats

Open

$5.88

Volume

13.71K

Market cap

$84.24M

Prev. close

$5.81

Impl / hst vl

-

Open interest

$0.00

$5.70

Day’s Range

$6.15

$5.50

52W Range

$7.71

Valuation

27
Valuation score
Overvalued
P/E
-
P/S
1.40
P/B
18.97
Current ratio
0.98
Debt / Equity
-1.64
ROE
-58.02%
Gross margin
46.65%
Income growth
-204.10%
FCF growth
-30.40

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$12.24
The top 3 analysts forecasts that 12-month price may increase by 110.67%, with a low of $12.12 and a high of $12.60
$12.12
Low
$12.24
Avg
$12.60
High
Current price

Earnings

Q1 ‘26 revenue
$16.56M
Q1 ‘26 net income
-$279.00K
Revenue
Net income
Previous EPS
$0.02
Estimate EPS
$0.09
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply